{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:23:27Z","timestamp":1787664207041,"version":"build-2736575974"},"reference-count":79,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Minister of Science under the Regional Initiative of Excellence Program","award":["52.660.203-110"],"award-info":[{"award-number":["52.660.203-110"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease in which fatigue and sleep disturbances, in addition to articular symptoms, are of significant importance. These symptoms are among the most common and burdensome complaints reported by patients; they affect their daily functioning and quality of life, and can also exacerbate one another. Currently, the treatment of RA focuses not only on reducing inflammatory activity and preventing structural damage, but also on improving outcomes that matter most to patients. In modern RA treatment, Janus kinase inhibitors (JAKis) are becoming increasingly important; by inhibiting the JAK\/STAT pathway, they limit the activity of cytokines involved in the inflammatory response. This review aimed to analyse the effect of selected JAKis on fatigue and sleep quality in patients with RA. An analysis of available study results showed that baricitinib, filgotinib, tofacitinib and upadacitinib reduce fatigue severity. In many cases, improvement was observed as early as the initial stages of treatment and persisted at later follow-up points. At the same time, the extent of this improvement was not uniform and depended on the drug used, the dose, the patient population, and the assessment method adopted. Some analyses also suggested that this effect may have been partly due to reduced pain and improved disease activity. The data on sleep quality are less extensive, but the results suggest that tofacitinib and upadacitinib may also have a beneficial effect in this regard. With tofacitinib, improvements in sleep quality were observed early, affected multiple sleep domains, and, in some studies, persisted over the long term. For upadacitinib, an improvement in sleep quality appeared to be associated with disease control and remission. The smaller number of studies on sleep quality than on fatigue highlights the need to consider this parameter more thoroughly when assessing the efficacy of JAKi treatment and emphasises the importance of a more holistic approach in clinical practice.<\/jats:p>","DOI":"10.3390\/jcm15176559","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:57:17Z","timestamp":1787662637000},"page":"6559","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of JAK Inhibitors on Fatigue and Sleep Quality in Patients with Rheumatoid Arthritis: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1086-7225","authenticated-orcid":false,"given":"Aleksandra","family":"Kowalska","sequence":"first","affiliation":[{"name":"Department of Mental and Psychosomatic Diseases, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0165-459X","authenticated-orcid":false,"given":"Aleksandra","family":"Borkowska","sequence":"additional","affiliation":[{"name":"Department of Mental and Psychosomatic Diseases, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7687-7613","authenticated-orcid":false,"given":"Aleksandra","family":"Jawoszek","sequence":"additional","affiliation":[{"name":"Department of Mental and Psychosomatic Diseases, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-7532","authenticated-orcid":false,"given":"Grzegorz","family":"Chmielewski","sequence":"additional","affiliation":[{"name":"Department of Mental and Psychosomatic Diseases, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0035-4314","authenticated-orcid":false,"given":"\u0141ukasz","family":"Ja\u015bkiewicz","sequence":"additional","affiliation":[{"name":"Department of Human Physiology and Pathophysiology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7857-347X","authenticated-orcid":false,"given":"Magdalena","family":"Krajewska-W\u0142odarczyk","sequence":"additional","affiliation":[{"name":"Department of Mental and Psychosomatic Diseases, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and Management of Rheumatoid Arthritis: A Review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e32825","DOI":"10.2196\/32825","article-title":"Sleep Disturbance and Quality of Life in Rheumatoid Arthritis: Prospective mHealth Study","volume":"24","author":"McBeth","year":"2022","journal-title":"J. Med. Internet Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.20539","article-title":"Impact of Fatigue on Health-Related Quality of Life in Rheumatoid Arthritis","volume":"51","author":"Rupp","year":"2004","journal-title":"Arthritis Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/clinpract12040062","article-title":"The Assessment of Fatigue in Rheumatoid Arthritis Patients and Its Impact on Their Quality of Life","volume":"12","author":"Dar","year":"2022","journal-title":"Clin. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","article-title":"A Structured Literature Review of the Burden of Illness and Unmet Needs in Patients with Rheumatoid Arthritis: A Current Perspective","volume":"36","author":"Taylor","year":"2016","journal-title":"Rheumatol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Constantin-Teodosiu, D., and Constantin, D. (2021). Molecular Mechanisms of Muscle Fatigue. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111587"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4103\/SINGAPOREMEDJ.SMJ-2021-118","article-title":"Approach to Fatigue in Primary Care","volume":"63","author":"Ho","year":"2022","journal-title":"Singap. Med. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1503\/cmaj.090647","article-title":"Diagnoses during Follow-up of Patients Presenting with Fatigue in Primary Care","volume":"181","author":"Nijrolder","year":"2009","journal-title":"CMAJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e32431","DOI":"10.1016\/j.heliyon.2024.e32431","article-title":"The Parameter of the Sick Building Syndrome: A Systematic Literature Review","volume":"10","author":"Subri","year":"2024","journal-title":"Heliyon"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41584-024-01135-3","article-title":"Update on the Pathophysiology and Treatment of Primary Sj\u00f6gren Syndrome","volume":"20","author":"Baldini","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-0041-1732827","article-title":"Role of Hepcidin in Anemia of Chronic Disease in Rheumatoid Arthritis","volume":"13","author":"Nita","year":"2021","journal-title":"J. Lab. Physicians"},{"key":"ref_12","first-page":"44","article-title":"Insomnia: A Current Review","volume":"121","author":"Naha","year":"2024","journal-title":"Mo. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e14035","DOI":"10.1111\/jsr.14035","article-title":"The European Insomnia Guideline: An Update on the Diagnosis and Treatment of Insomnia 2023","volume":"32","author":"Riemann","year":"2023","journal-title":"J. Sleep Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bandinelli, F., Delle Sedie, A., Mallia, I., Mauro, I., Pecani, N., Carli, L., Esti, L., Di Carlo, M., Carotti, M., and Salaffi, F. (2025). Causes of Sleep Disturbance in Early ASAS Spondyloarthritis: A Retrospective Long-Term Experience. J. Pers. Med., 15.","DOI":"10.3390\/jpm15010031"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101423","DOI":"10.1016\/j.berh.2019.06.005","article-title":"The Prevalence and Impact of Comorbid Fibromyalgia in Inflammatory Arthritis","volume":"33","author":"Zhao","year":"2019","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.sleep.2012.09.020","article-title":"Nocturnal Sleep, Daytime Sleepiness and Fatigue in Fibromyalgia Patients Compared to Rheumatoid Arthritis Patients and Healthy Controls: A Preliminary Study","volume":"14","author":"Roehrs","year":"2013","journal-title":"Sleep Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/rheumatology\/key075.533","article-title":"Concomitant Fibromyalgia Complicating Chronic Inflammatory Arthritis: A Systematic Review and Meta-Analysis","volume":"57","author":"Duffield","year":"2018","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/acr.25685","article-title":"Objectively Measured Sleep Disorders in Rheumatoid Arthritis and Their Association With Disease Activity","volume":"78","author":"Katz","year":"2026","journal-title":"Arthritis Care Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/acr.24999","article-title":"Sleep Disorders Among Individuals With Rheumatoid Arthritis","volume":"75","author":"Katz","year":"2023","journal-title":"Arthritis Care Res."},{"key":"ref_20","first-page":"3498","article-title":"JAK\/STAT Pathway in Pathology of Rheumatoid Arthritis (Review)","volume":"20","author":"Ciobanu","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12026-021-09173-9","article-title":"Effect of Interleukin-6, -17, -21, -22, and -23 and STAT3 on Signal Transduction Pathways and Their Inhibition in Autoimmune Arthritis","volume":"69","author":"Tabarkiewicz","year":"2021","journal-title":"Immunol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.intimp.2015.12.011","article-title":"Role of Interleukin-23 as a Biomarker in Rheumatoid Arthritis Patients and Its Correlation with Disease Activity","volume":"31","author":"Zaky","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Burja, B., Mertelj, T., and Frank-Bertoncelj, M. (2020). Hi-JAKi-Ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors. Front. Med., 7.","DOI":"10.3389\/fmed.2020.00124"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"T\u00f3th, L., Juh\u00e1sz, M.F., Szab\u00f3, L., Abada, A., Kiss, F., Hegyi, P., Farkas, N., Nagy, G., and Helyes, Z. (2022). Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031246"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chmielewski, G., Majewski, M.S., Kuna, J., Mikiewicz, M., and Krajewska-W\u0142odarczyk, M. (2023). Fatigue in Inflammatory Joint Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512040"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10067-015-3035-6","article-title":"The Prevalence of Severe Fatigue in Rheumatic Diseases: An International Study","volume":"35","author":"Overman","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.apmr.2015.09.022","article-title":"Effects of Person-Centered Physical Therapy on Fatigue-Related Variables in Persons With Rheumatoid Arthritis: A Randomized Controlled Trial","volume":"97","author":"Feldthusen","year":"2016","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_28","first-page":"1361","article-title":"Trajectories in Early Rheumatoid Arthritis Related Fatigue over 10 Years: Results from the ESPOIR Cohort","volume":"40","author":"Combe","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5114\/reum.2017.67600","article-title":"Fatigue and Sleep Quality in Rheumatoid Arthritis Patients during Hospital Admission","volume":"55","author":"Szady","year":"2017","journal-title":"Reumatologia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s10067-015-2875-4","article-title":"Sleep Quality and Correlates of Poor Sleep in Patients with Rheumatoid Arthritis","volume":"34","author":"Esbensen","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Radmanovi\u0107, O., Janji\u0107, V., Veselinovi\u0107, M., Ko\u010dovi\u0107, A., Muri\u0107, N., \u0110or\u0111i\u0107, M., Fetahovi\u0107, E., Suboti\u0107, N., Milojevi\u0107, A., and Stojkovi\u0107, M. (2025). The Impact of Insomnia on the Clinical Course and Treatment Outcomes of Rheumatoid Arthritis. Biomedicines, 13.","DOI":"10.3390\/biomedicines13102535"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.rbr.2016.06.002","article-title":"Rheumatoid Arthritis and Sleep Quality","volume":"57","author":"Goes","year":"2017","journal-title":"Rev. Bras. Reumatol. (Engl. Ed.)"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3906\/sag-1506-82","article-title":"Sleep Quality and Factors Affecting Sleep in Elderly Patientswith Rheumatoid Arthritis in Turkey","volume":"46","author":"Pehlivan","year":"2016","journal-title":"Turk. J. Med. Sci."},{"key":"ref_34","first-page":"e72417","article-title":"Frequency of Sleep Disorders in Rheumatoid Arthritis Patients","volume":"16","author":"Yaseen","year":"2024","journal-title":"Cureus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/rheumatology\/37.1.71","article-title":"Sleep in Rheumatoid Arthritis: A Comparison with Healthy Subjects and Studies of Sleep\/Wake Interactions","volume":"37","author":"Drewes","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/rheumatology\/39.11.1287","article-title":"A Longitudinal Study of Clinical Symptoms and Sleep Parameters in Rheumatoid Arthritis","volume":"39","author":"Drewes","year":"2000","journal-title":"Rheumatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/msc.1052","article-title":"Using Actigraphy to Measure Sleep Patterns in Rheumatoid Arthritis: A Pilot Study in Patients Taking Night-Time Prednisone","volume":"11","author":"Clarke","year":"2013","journal-title":"Musculoskelet. Care"},{"key":"ref_38","first-page":"675","article-title":"Deciphering the Temporal Link between Pain and Sleep in a Heterogeneous Chronic Pain Patient Sample: A Multilevel Daily Process Study","volume":"35","author":"Tang","year":"2012","journal-title":"Sleep"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ju\u00e1rez-Rojop, I.E., Fres\u00e1n, A., Genis-Mendoza, A.D., Cerino-Palomino, C., Nolasco-Rosales, G.A., Gonz\u00e1lez-Castro, T.B., L\u00f3pez-Narv\u00e1ez, M.L., Olan, F., Villar-Soto, M., and Tovilla-Z\u00e1rate, C.A. (2023). Prevalence of Poor Sleep Quality and Associated Factors in Individuals with Rheumatoid Arthritis: A Cross-Sectional Study. Medicina, 59.","DOI":"10.3390\/medicina59091633"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"v35","DOI":"10.1093\/rheumatology\/kez413","article-title":"Fatigue in Inflammatory Rheumatic Disorders: Pathophysiological Mechanisms","volume":"58","author":"Korte","year":"2019","journal-title":"Rheumatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40744-023-00583-9","article-title":"Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate","volume":"10","author":"Tanaka","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/rheumatology\/kez346","article-title":"Predictors of Fatigue in Rheumatoid Arthritis","volume":"58","author":"Druce","year":"2019","journal-title":"Rheumatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.2147\/JIR.S414739","article-title":"Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases","volume":"16","author":"Massalska","year":"2023","journal-title":"J. Inflamm. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1759720X211006964","DOI":"10.1177\/1759720X211006964","article-title":"Patient-Reported Outcomes from a Randomized, Double-Blind, Placebo Controlled, Phase III Study of Baricitinib versus Placebo in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Therapy: Results from the RA-BALANCE Study","volume":"13","author":"Yang","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40744-021-00415-8","article-title":"Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials","volume":"9","author":"Sholter","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e000410","DOI":"10.1136\/rmdopen-2016-000410","article-title":"Patient-Reported Outcomes from a Phase III Study of Baricitinib in Patients with Conventional Synthetic DMARD-Refractory Rheumatoid Arthritis","volume":"3","author":"Emery","year":"2017","journal-title":"RMD Open"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","article-title":"Patient-Reported Outcomes from a Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis: Secondary Analyses from the RA-BEAM Study","volume":"76","author":"Keystone","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13075-017-1410-1","article-title":"Patient-Reported Outcomes of Baricitinib in Patients with Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment","volume":"19","author":"Schiff","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/RHU.0000000000001924","article-title":"Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results from 2 Baricitinib Phase 3 Clinical Trials","volume":"29","author":"Fautrel","year":"2023","journal-title":"J. Clin. Rheumatol."},{"key":"ref_50","first-page":"230","article-title":"Efficacy and Safety of Filgotinib in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs): A Meta-Analysis of Randomized Controlled Trials","volume":"1","author":"Wang","year":"2022","journal-title":"ARP Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-021-02677-7","article-title":"The Impact of Filgotinib on Patient-Reported Outcomes and Health-Related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Studies","volume":"24","author":"Bingham","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13075-020-02324-7","article-title":"Associations between Patient Global Assessment Scores and Pain, Physical Function, and Fatigue in Rheumatoid Arthritis: A Post Hoc Analysis of Data from Phase 3 Trials of Tofacitinib","volume":"22","author":"Strand","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13075-022-02724-x","article-title":"The Impact of Tofacitinib on Fatigue, Sleep, and Health-Related Quality of Life in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Data from Phase 3 Trials","volume":"24","author":"Bartlett","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e000742","DOI":"10.1136\/rmdopen-2018-000742","article-title":"Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Phase III Randomised Clinical Trials of Tofacitinib","volume":"5","author":"Bird","year":"2019","journal-title":"RMD Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40744-022-00523-z","article-title":"Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients Who Are CCP","volume":"10","author":"Harrold","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/03007995.2025.2515280","article-title":"Real-World Clinical Outcomes of Patients with Moderate-to-Severe Rheumatoid Arthritis Initiating Upadacitinib in the United Kingdom: Final Analysis from a Prospective Observational Cohort Study (ENDEAVOUR)","volume":"41","author":"Taylor","year":"2025","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-019-2037-1","article-title":"Upadacitinib Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Results from SELECT-NEXT","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-022-02813-x","article-title":"Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12- and 24-Week Results of a Phase 3 Trial","volume":"24","author":"Bergman","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40744-024-00694-x","article-title":"Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study","volume":"11","author":"Kato","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40744-024-00639-4","article-title":"Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry","volume":"11","author":"Baker","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1007\/s12325-024-02948-0","article-title":"A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor","volume":"41","author":"Caporali","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1093\/rheumatology\/keab158","article-title":"Upadacitinib Improves Patient-Reported Outcomes vs Placebo or Adalimumab in Patients with Rheumatoid Arthritis: Results from SELECT-COMPARE","volume":"60","author":"Strand","year":"2021","journal-title":"Rheumatology"},{"key":"ref_63","first-page":"3","article-title":"Sleep and Inflammation: A Bidirectional Relationship","volume":"29","author":"Engert","year":"2025","journal-title":"Somnologie"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kuna, K., Szewczyk, K., Gabryelska, A., Bia\u0142asiewicz, P., Ditmer, M., Strzelecki, D., and Sochal, M. (2022). Potential Role of Sleep Deficiency in Inducing Immune Dysfunction. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092159"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"RP99999","DOI":"10.7554\/eLife.99999.3","article-title":"Glia-Mediated Gut-Brain Cytokine Signaling Couples Sleep to Intestinal Inflammatory Responses Induced by Oxidative Stress","volume":"13","author":"Malita","year":"2025","journal-title":"eLife"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active Rheumatoid Arthritis: A Randomized Trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in Patients with Rheumatoid Arthritis Receiving Methotrexate: Twelve-Month Data from a Twenty-Four-Month Phase III Randomized Radiographic Study","volume":"65","author":"Tanaka","year":"2013","journal-title":"Arthritis Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1109071","article-title":"Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23004","article-title":"Tofacitinib in Combination with Conventional Disease-Modifying Antirheumatic Drugs in Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial","volume":"69","author":"Strand","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_70","first-page":"848","article-title":"Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Patient-Reported Outcomes from the 24-Month Phase 3 ORAL Scan Study","volume":"38","author":"Strand","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.22453","article-title":"Tofacitinib with Methotrexate in Third-Line Treatment of Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase III Trial","volume":"67","author":"Strand","year":"2015","journal-title":"Arthritis Care Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13075-015-0825-9","article-title":"Effects of Tofacitinib Monotherapy on Patient-Reported Outcomes in a Randomized Phase 3 Study of Patients with Active Rheumatoid Arthritis and Inadequate Responses to DMARDs","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e000308","DOI":"10.1136\/rmdopen-2016-000308","article-title":"Tofacitinib versus Methotrexate in Rheumatoid Arthritis: Patient-Reported Outcomes from the Randomised Phase III ORAL Start Trial","volume":"2","author":"Strand","year":"2016","journal-title":"RMD Open"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13075-019-2059-8","article-title":"Effects of Upadacitinib on Patient-Reported Outcomes: Results from SELECT-BEYOND, a Phase 3 Randomized Trial in Patients with Rheumatoid Arthritis and Inadequate Responses to Biologic Disease-Modifying Antirheumatic Drugs","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_75","first-page":"1283","article-title":"Improvement of Sleep Impairment in Patients with Rheumatoid Arthritis Achieving Remission or Pain Relieve with Upadacitinib: Results from the Post-Marketing Observational Sleera Study","volume":"82","author":"Prillwitz","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.ard.2026.01.023","article-title":"EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biologic Disease-Modifying Antirheumatic Drugs: 2025 Update","volume":"85","author":"Smolen","year":"2026","journal-title":"Ann. Rheum. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse Events Associated with JAK Inhibitors in 126,815 Reports from the WHO Pharmacovigilance Database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The Infection Risks of JAK Inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert. Rev. Clin. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6559\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:03:56Z","timestamp":1787663036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":79,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176559"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176559","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}